Assessments

All patients were analyzed when they were in the “on” state of medication (1–1.5 hours after taking medication). Demographic data were collected, including gender, age, duration of the disease and treatments. We assessed the medication doses used by individuals with PD. Furthermore, the following evaluations were used: the H&Y scale [15], the Unified Parkinson’s Disease Rating Scale (UPDRS) [16], the Parkinson’s Disease Fatigue Scale (PFS) [17] and the Beck Anxiety Inventory (BAI) [18].

The evaluations were made by two trained and experienced evaluators (Evaluator 1 and Evaluator 2) and at two time points (1st day and 2nd day) separated by an interval of 7 days. On the 1st day, all evaluations were performed (the PFS, UPDRS, BAI, and PAS-BV) by only one evaluator (EV1), and the second evaluator (EV2) only administered the PAS-BV. On the 2nd day, only one evaluator (EV1) administered the PAS-BV. There was a 15-minute interval between the PAS-BV evaluations made by the evaluators (EV1 and EV2) on the first day.